WO2005089788A1 - 癌治療のための薬剤 - Google Patents
癌治療のための薬剤 Download PDFInfo
- Publication number
- WO2005089788A1 WO2005089788A1 PCT/JP2005/004123 JP2005004123W WO2005089788A1 WO 2005089788 A1 WO2005089788 A1 WO 2005089788A1 JP 2005004123 W JP2005004123 W JP 2005004123W WO 2005089788 A1 WO2005089788 A1 WO 2005089788A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- drug
- cancer
- amino acid
- cytotoxic activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention provides a ratatoferin hydrolysis mixture having an effect of enhancing the cytotoxic activity of an antibody drug in cancer antibody therapy, or a rat rat tofferin partial peptide that can be separated from the ratatoferin hydrolysis mixture, or
- the present invention relates to a drug containing, as an active ingredient, a partial peptide of ratatofurin that can be prepared by chemical synthesis or the like. More specifically, the present invention relates to a drug having an effect of increasing the sensitivity of an antibody drug to cancer cells having resistance to the antibody drug.
- the mechanism of action of antibody drugs against these malignant tumors can be roughly classified into three mechanisms. It is. That is, the first mechanism is that when an antibody binds to the cell surface of a malignant tumor, some signal is transmitted to the tumor cells, causing cell death. Second, the effector cells (neutrophils, macrophages, NK cells, etc.) present in the body Recognize antibodies attached to tumor cells by antigen-antibody reaction and kill tumor cells by cytotoxic activity It is. Third, complement components in the body recognize antibodies attached to tumor cells by antigen-antibody reaction, and cause cytotoxic effects by the classical pathway of the activation pathway of the complement system, causing tumor cells. The mechanism is killing (for example, Non-Patent Document 2).
- Ratatofuericin (registered trademark by the present applicant) is a novel peptide isolated for the first time from the enzymatic hydrolyzate of Psi'ratatoferrin by the inventors of the present invention (for example, Patent Document 1 ).
- Ratatophelicin isolated from Pseudorathatoferin has, for example, the amino acid sequence of SEQ ID NO: 2.
- Ratatofuricin is a source of various human and animal diseases. It is a very useful substance that has antibacterial activity at a low concentration against a wide range of microorganisms such as gram-positive and gram-negative bacteria and yeasts that cause it.
- ratatofuricin contains chemicals and chemically synthesized amino acid derivatives. Because it is a natural peptide, it is healthy and safe for humans and animals. This is because ratatofuerisin is naturally produced in the human stomach by gastro-pepsin decomposition of ratatofurin contained in milk which is usually consumed. Therefore, ratatofuricin can be used as a safe and effective antibacterial agent in a wide variety of products such as eye drops, oral agents, cosmetics, dermatological agents, clinical foods, pet products, etc. ing.
- Patent Document 2 an antitumor agent
- Patent Document 3 an antitumor agent for parenteral use
- Patent Document 4 an oral cancer metastasis inhibitor
- All of these technologies rely on the effect of ratatofurin directly acting on tumor cells, and the antitumor activity of antibody drugs, which has been attracting attention in cancer treatment in recent years, is enhanced by the cytotoxic activity of antibody drugs. The effect is different.
- Patent Document 1 Patent No. 2818056
- Non-patent Document 2 Latest Illustrated Immunology, edited by Shigeo Koyasu, edited by Taro Kinoshita, 2003, p. 35-50
- Non-Patent Document 3 Blood Frontier, by Kiyohiko Hata, Vol. 12, No. 11, 2002, p. 65-71
- Non-Patent Document 4 Oncogene, Vol. 22, 2003, p. 7359-7368 Disclosure of the invention
- the present invention contains a highly safe drug which has no side effect and has an effect of enhancing the cytotoxic activity of an antibody drug in antibody therapy for cancer, particularly antibody therapy for cancer having resistance, and the drug. It is an object of the present invention to provide a method for enhancing the cytotoxic activity of a food or drink or an antibody drug.
- the present inventors have focused on a technique that more effectively enhances the cytotoxic activity of an antibody drug and leads to an improvement in therapeutic results.
- the state where resistance to the antibody drug has been confirmed in patients with malignant tumors Even so, if the sensitivity of the target tumor cells to the antibody drug is enhanced, it may not be possible to fully exert the cytotoxic activity of the complement system.
- the hydrolysis mixture of ratatoferin and a peptide that can be separated from the ratatoferin hydrolysis mixture act on the target tumor cells, It was found that the sensitivity to a drug was enhanced, and the present invention was completed.
- the present invention is essentially different from the conventionally known antitumor effect of ratatoferin, and is particularly effective for cancers for which almost no effective treatments or drugs have been found so far.
- antibody therapy which is considered to be an antibody therapy
- the present invention relates to a novel drug containing a partial peptide of ratatofurin as an active ingredient which can be prepared by the above method and the use thereof.
- the first invention of the present application to solve the above-mentioned problems can be obtained by hydrolyzing ratatoferin with a hydrolase, and enhances the cytotoxic activity of an antibody drug in antibody therapy for cancer.
- a drug for enhancing the cytotoxic activity of an antibody drug in antibody therapy for cancer comprising a ratatoferin hydrolyzate having an action as an active ingredient.
- the hydrolase is pepsin.
- the number average molecular weight of the ratatofurin hydrolyzate is 500-5000.
- the cancer is any one of breast cancer, B-cell lymphoma, and colorectal cancer.
- the cancer has resistance to an antibody drug.
- the action of enhancing the cytotoxic activity of the antibody drug is an action of increasing the sensitivity of the antibody drug to target tumor cells.
- the cancer is any one of breast cancer, B-cell lymphoma, and colorectal cancer.
- the cancer is a cancer resistant to an antibody drug.
- Another aspect of the second invention is the use of the peptide in the production of the drug.
- Another embodiment of the second invention is directed to antibody therapy for cancer using an antibody drug.
- a method for enhancing the cytotoxic activity of the antibody drug, wherein the method comprises administering the hydrolyzate of extraferric ferrin to a patient.
- the invention of the present application also provides a food or drink containing the drug of the first invention or the second invention.
- the ratatofurin hydrolyzate has a number average molecular weight of 500-5000.
- the antibody drug is an anti-CD20 antibody, an anti-HER2 monoclonal antibody, or an anti-17-1A (human tumor-associated epithelial cell adhesion factor) antibody.
- the above-mentioned active ingredient has the same effect as that of the above-mentioned drug by being contained in a food or drink indicated to enhance the cytotoxic activity of the antibody drug in antibody therapy for cancer.
- a drug for enhancing the cytotoxic activity of an antibody drug in cancer antibody therapy of the present invention or a drug for cancer antibody therapy (hereinafter sometimes simply referred to as “the drug of the present invention”).
- the active ingredient can be obtained by hydrolyzing ratatofurin with a hydrolase, and has an action of enhancing the cytotoxic activity of an antibody drug in cancer antibody therapy (hereinafter referred to as “ratatofurin hydrolyzate”). Hydrolyzed mixture), or a mixture of one or more of the following peptides (a) and (d) (hereinafter also referred to as “ratatophenine partial peptide”).
- the ratatoferrin hydrolysis mixture which is an active ingredient of the drug of the present invention, and the ratatofurin partial peptide (ratatofurin partial peptide) that can be separated from the ratatophrine hydrolysis mixture may be prepared using ratatoferin as a starting material.
- ratatoferin is commercially available ratatoferin, colostrum, transitional milk, normal milk, end-stage milk of mammals (for example, humans or pests), or skim milk or whey, which is a processed product of these milks.
- Radical ferrin obtained by separating from the above-mentioned raw material by a conventional method such as ion exchange chromatography can be used.
- lactoferrin manufactured on an industrial scale (for example, manufactured by Morinaga Milk Industry Co., Ltd.). Furthermore, ratatofurin produced in microorganisms, animal cells, transgenic animals, and the like by genetic engineering techniques can also be used.
- hydrolases examples include pepsin, pancreatin, trypsin, chymotrypsin, protease derived from Aspergillus oryzae, and protease derived from Streptomyces griseus.
- hydrolases include pepsin, pancreatin, trypsin, chymotrypsin, protease derived from Aspergillus oryzae, and protease derived from Streptomyces griseus.
- hydrolases may be used. When two or more enzymes are used, each enzyme reaction may be performed simultaneously or separately. In the present invention, it is particularly preferable to use pepsin. It is also possible to use an endo-type protease in combination with an exo-type hydrolase.
- the hydrolysis reaction time is preferably set so as to reach a preferable decomposition rate while monitoring the decomposition rate of the enzyme reaction. In order to obtain a ratatofurin hydrolysis mixture which is an active ingredient of the drug of
- the protein degradation rate can be determined by, for example, measuring the total nitrogen content of a sample by the Kjeldahl method (edited by the Japan Food Industry Association, “Food Analysis Method”, page 102, Korin Co., Ltd., 1984).
- the formal nitrogen content of the sample was measured by the formol titration method (Mitsuda et al., “Food Engineering Experiment”, Vol. 1, p. 547, Yokendo, 1970), and the calculated value was calculated from the following formula based on the measured values.
- the enzymatic reaction may be stopped. Termination of the enzyme reaction is carried out by inactivating the enzyme in the hydrolyzed solution, and can be carried out by a conventional heat inactivation treatment.
- the heating temperature and the holding time for the heat inactivation treatment can be set as appropriate under conditions that allow sufficient inactivation in consideration of the thermal stability of the enzyme used. This can be done with a hold time of 12 seconds per minute.
- the pH of the resulting reaction solution is preferably adjusted to 5.5-7 with an acid such as citric acid. When there are insolubles in the ratatophrine hydrolysis mixture, they can be removed by centrifugation or filtration.
- the number average molecular weight (Number Average of Molecular Weight) is described, for example, in the literature (edited by The Society of Biopolymers, Japan, “Basics of Polymer Science”, pp. 116-119, Tokyo Chemical Dojin, 1978). As shown, the average value of the molecular weight of the polymer compound is shown based on different indices as follows.
- the ratatofurin hydrolyzed mixture thus obtained can be used as an active ingredient of the drug of the present invention as it is, or can be freeze-dried or spray-dried by a conventional method and stored as a powder. Furthermore, it can be used for producing ratatoferrin partial peptide which is another active ingredient of the drug of the present invention. Further, the ratatoferin hydrolysis mixture may be obtained by adding a ratatopherin partial peptide to the ratatofurin hydrolysis product obtained as described above.
- ratatoferrin partial peptide examples include a peptide having an amino acid sequence of amino acids 36 to 60 or a peptide having an amino acid sequence of amino acid 36 in amino acid sequence 1J described in SEQ ID NO: 1 in the sequence listing. And a peptide consisting of 61 amino acid sequences (SEQ ID NO: 2).
- a peptide having the amino acid sequence of amino acids 36 to 60 (SEQ ID NO: 3) is referred to as ratatoferin F-F
- a peptide having the amino acid sequence of amino acids 36 to 61 is referred to as ratatoferin F.
- lactoferrin F—A 1: 10—2: 3 is particularly preferred.
- F-A produces, for example, the ratatofurin hydrolysis mixture prepared as described above.
- a method for producing a synthetic peptide by chemical synthesis and a method for producing a recombinant peptide by using a genetic engineering technique utilizing genetic recombination technology or the like. , Etc. may also be used.
- an appropriate primer is prepared based on a nucleotide sequence encoding an amino acid sequence containing the region, and a cDNA containing the target nucleotide sequence is prepared using the primer.
- Type III can be obtained by amplifying the base sequence by PCR or the like and expressing the obtained base sequence using an appropriate expression system.
- Ratatoferin F -F or ratatoferin F — A that may contain
- the number of substitutions, deletions, insertions, additions or inversions of the acid residue is preferably 1-12, more preferably 1-18, and particularly preferably 1-15.
- substitution of amino acid residues is preferably substitution between amino acids having similar properties, so-called conservative substitution.
- Such a variant of ratatophrine F-F or ratatoferin F—A may be ratatoferin F-F or ratatoferrin F-A.
- the added amino acid is from position 36 to the N-terminal of ratatofurin.
- amino acid to be added may be any amino acid as long as the variant has a desired action.
- the ratatoferin hydrolysis mixture or ratatoferin partial peptide that can be used in the present invention has an effect of enhancing the cytotoxic activity of an antibody drug in antibody therapy for cancer, and the effect is demonstrated by Propidium iodide (PI: Dojindo (Catalog number: P378) Cytometry, Vol. 8, No. 4, 1987, pp. 421-426], or
- Calcein-AM manufactured by Dojindo, catalog number 341-07901
- Apoptosis, Vol. 3, No. 3, 1998, pp. 195-202 [Apoptosis, Vol. 3, No. 3, 1998, pp. 195-202]. .
- the measurement method will be described in detail in Examples described later.
- the drug of the present invention contains human orally or non-orally through a ratatopurin hydrolysis mixture or ratatofurin partial peptide, or a combination thereof with a pharmaceutically acceptable preparation carrier. It can be administered to a mammal.
- an antibody drug is further combined with the above components.
- the formulation of the drug of the present invention is not particularly limited and can be appropriately selected depending on the purpose of treatment. Specifically, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, syrups Suppositories, injections, ointments, patches, eye drops, nasal drops and the like.
- excipients in the formulation, excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents, surfactants, solvents for injections, etc., which are commonly used as pharmaceutical carriers for ordinary pharmaceuticals, Additives can be used.
- the administration time of the drug of the present invention is not particularly limited, and may be before, after or simultaneously with the administration of the antibody drug, and may be simultaneous with the antibody drug. In addition, the timing of administration can be appropriately selected.
- the administration form is determined according to the preparation form, the patient's age, sex, other conditions, the degree of the patient's symptoms, and the like.
- the dose of the active ingredient of the preparation of the present invention is appropriately selected depending on the usage, age, sex, degree of disease, other conditions, and the like of the patient.
- the amount of the ratatoferrin hydrolysis mixture or ratatofurin partial peptide as the active ingredient is 0.0001 60 mgZkg / day, preferably 0.01 0.01 mg / kg / day. It can be administered once a day or divided into multiple doses.
- the agent of the present invention is useful for treating any of cancer, for example, breast cancer, B-cell lymphoma, colorectal cancer and the like. Thus, it is useful as a therapeutic agent, therapeutic effect enhancer, or therapeutic adjuvant in treatment using an antibody drug.
- drugs of the present invention drugs containing an antibody drug together with a ratatophrine hydrolysis mixture or ratatoferin partial peptide can be used as a drug for antibody therapy of cancer.
- an antibody drug or a drug for enhancing the cytotoxic activity of the antibody drug of the present invention can be further administered.
- the drug of the present invention is extremely effective especially for the above-mentioned cancers, which are resistant to antibody drugs.
- Antibody drugs that can be used in the present invention include anti-CD20 antibody (rituximab), anti-HER2 monoclonal antibody (trastuzumab), anti-17-1A (human tumor-associated epithelial cell adhesion factor). )
- Antibodies (edrecolomab) and the like, and antibody drugs that can be used in antibody therapy in cancer treatment can also be used. Further, the present invention is not limited to currently known antibody drugs, and antibody drugs to be developed in the future can also be used.
- the agent of the present invention is preferably used together with an antibody drug in antibody therapy (regardless of whether the administration is performed at the same time or not), and the known preventive / therapeutic agent for the above-mentioned cancer disease (enhancement) Agents (including adjuvants) can also be used in combination. By using them together, the effects of preventing and treating the above-mentioned cancer diseases can be enhanced, and it is also possible to reduce the dose of the above-mentioned prophylactic 'therapeutic agents used in combination. Further, the agent for preventing or treating a cancer disease used in combination may be contained as an active ingredient in the composition of the drug of the present invention, or may be separately contained without being contained in the composition of the drug of the present invention. It may be commercialized in combination as a drug and combined at the time of use.
- the drug of the present invention may also be contained in food or drink (beverage or food).
- food or drink beverage or food.
- the form and properties are not particularly limited as long as they can be taken orally without impairing the effects of the active ingredients, and raw materials usually used in foods and drinks other than containing the active ingredients are used. And can be produced by a usual method.
- the food or drink of the present invention is used to enhance the cytotoxic activity of an antibody drug used for antibody therapy for cancer, and is labeled with a label indicating that it can be used, for example, “for antibody therapy for cancer.
- a food or drink containing a ratatoferin hydrolysis mixture or ratatoferin partial peptide which is described as for enhancing the cytotoxic activity of antibody drugs, or ⁇ enhance the cytotoxic activity of antibody drugs used in antibody therapy for cancer.
- the food or drink of the present invention may be referred to as an antibody drug used in antibody therapy for cancer.
- an antibody drug used in antibody therapy for cancer For enhancing the cytotoxic activity of "."
- the wording used for performing the above display is not limited to the wording "for enhancing the cytotoxic activity of an antibody drug used for antibody therapy for cancer", but may be any other wording. Needless to say, any language that indicates an auxiliary effect or an enhancing effect on the cytotoxic activity of an antibody drug used for antibody therapy of cancer is included in the scope of the present invention. Such words include, for example, various words that remind the consumer of the enhancement of the cytotoxic activity of the antibody drug used in antibody therapy for cancer or the auxiliary effect of the antibody drug used in antibody therapy for cancer.
- the display based on the use of is also possible. For example, “I have resistance to antibody drugs. Useful for reducing and eliminating risk factors (risks) such as cancer. " In the above display, the phrase "used for antibody therapy for cancer” may be omitted.
- the act of describing the above-mentioned use on the product or the packaging of the product according to the food and drink of the present invention and the transfer or delivery of the product or the product with the above-mentioned use described on the packaging of the product for the transfer or delivery Import, advertising on goods, price list or transaction documents, exhibiting or distributing the above-mentioned use, or describing the above-mentioned use in information containing these, and electromagnetically (such as the Internet) )
- the actions provided by the method can be exemplified.
- the display is preferably a display approved by the government or the like (for example, a display that is approved based on various systems determined by the government and is performed in a form based on such approval).
- a display that is approved based on various systems determined by the government and is performed in a form based on such approval.
- labeling as a health food, a functional food, an enteral nutrition food, a special use food, a nutritional food, a quasi-drug, and the like can be exemplified.
- Approved indications for example, foods for specified health use and indications approved under a similar system can be exemplified. Examples of the latter can include labeling as food for specified health use, labeling as food for conditional health use, labeling that affects the structure and function of the body, labeling for reducing disease risk, etc.
- the labeling as food for specified health use (especially the labeling of health use) specified in the Health Promotion Law Enforcement Regulations (Ordinance No. 86 of the Ministry of Health, Labor and Welfare on April 30, 2003) and similar Indications can be listed as typical examples.
- the hydrophobic carrier was regenerated by passing 10 mM hydrochloric acid and water through the column, and the pH of the eluate was adjusted to 7.0 with 1 N sodium hydroxide solution.
- the eluate containing the ratatopherin hydrolyzing peptide is passed through this column, washed with 30 liters of water to remove the salt of the buffer, and then 10 mM hydrochloric acid is passed through the column to elute the ratatopherin hydrolyzing peptide. After freeze-drying, about 10.5 g of powdery ratatofurin hydrolyzing peptide was obtained.
- the purity of the obtained ratatofurin hydrolyzed peptide was measured by HPLC, and as a result, the purity was 99%. Further, the amino acid sequence of the ratatopurinka syrup hydrolyzing peptide As a result of the measurement, the produced ratatoferin hydrolyzing peptide was ratatofurin F-F and
- RPMI1640 medium containing Penicillin-Streptomycin manufactured by Gibconed Earth: Catalog No. 15070-063 (manufactured by Sigma: Catalog No. R8758) [Hereinafter, this solution is referred to as “diluted solution”.
- a test sample 1 was prepared by preparing the ratatofurin hydrolysis mixture prepared in Production Example 1 so as to have a concentration of 1000 ⁇ g Zml.
- ratatoferin was diluted to 1000 / g / ml to prepare Control Sample 1.
- Target cell for measuring cytotoxicity of complement and antibody drugs human Burkitt's lymphoma Raji (ATCC CCL-86: American 'type' cultivation 'collection (10801 University Boulevard, Manassas, VA 20110) -2209, using from available) USA), was prepared Raji cell suspension was suspended with dilute solution to a cell number force 3 ⁇ 4 X 10 6 cells / ml.
- the antibody drug solution was prepared using rituximab recognizing the CD20 antigen (Zenyaku Kogyo: sold by Nippon Roche) to a concentration of 200 Aig / ml using a dilute solution.
- Human serum AB manufactured by Cosmo Bio: catalog number 832000027) was used as a complement solution.
- test sample group 1 100 parts each of the test sample 1 (group 4 ⁇ 2 holes), the control sample 1 (group 4 ⁇ 2 holes), or the diluted solution (group 4 ⁇ 2 holes)
- the test sample group was added to each of the samples, and they were called “test sample group 1”, “control sample group 1”, and “negative sample group 1”, respectively.
- the 24-well plate prepared as described above was cultured for 1 hour at 37 ° C and 5% carbon dioxide using an incubator (manufactured by Napco, catalog number 5300). The cells were collected, and the ratio of each dead cell was examined by the method using PI described above. Cytotoxic activity was calculated as 100% when all target cells were killed.
- Table 1 shows the results of this test.
- the cytotoxic activity of each sample group (“Test sample group 1”: 45.7%, “Control sample group 1”: 24.3%, “Negative sample group 1”: 30.7%) was confirmed.
- the lactoferrin hydrolysis mixture (test sample group 1) markedly enhanced cytotoxicity (compared to the negative sample group 1). About 50% increase).
- the control sample group 1 did not increase the cytotoxic activity compared to the negative sample group, indicating that the enhancement of the cytotoxic activity was specific to the ratatofurin hydrolysis mixture.
- the purpose of this study was to examine changes in the sensitivity of complement and antibody drugs to cytotoxic activity in target tumor cells cultured with the addition of ratatoferrin hydrolysis mixture during culture.
- Test sample 2 was prepared by diluting the ratatopherin hydrolysis mixture prepared in Production Example 1 with the dilution solution used in Test Example 1 to a concentration of 1000 / g / ml.
- Test sample group 2 Human Burkitt's lymphoma Raji was suspended in 6.3 ml of the diluted solution so that the number of cells became 2 ⁇ 10 5 cells / culture flask (manufactured by BD: Catalog No. 35-3014).
- test sample group 2 a group to which 0.7 ml of the above test sample 2 was added
- negative sample group 2 a group to which 0.7 ml of the diluting solution were added
- test sample group 2 the group of target tumor cells (test sample group 2) cultured for 3 days with the addition of the ratatopherin hydrolysis mixture was tested negative.
- the sensitivity to the cytotoxic activity of “complement + antibody drug” was clearly higher than that of sample group 2, and the potentiating effect revealed in Test Example 1 was Turned out to be.
- Test sample 3 was prepared by diluting the ratatopherin hydrolysis mixture prepared in Production Example 1 with the dilution solution used in Test Example 1 so as to be 1000 zgZml.
- Test sample 4 was prepared by diluting the ratatopherin hydrolyzed peptide prepared in Production Example 2 to 1000 ⁇ g Zml using the same dilution solution.
- the human Burkitt's lymphoma Raji was suspended using the above-mentioned dilution solution so that the cell number was 2 ⁇ 10 5 cells / ml to prepare a cell suspension, and the cell solution was transferred to a 96-well culture plate (manufactured by NUNC). : 50 ⁇ l (1 ⁇ 10 4 pieces) was added to each of the 18 wells of Catalog No. 167008). The 18 wells were divided into two groups, and one group (9 wells) was added with 10 ⁇ 1 of the antibody drug solution, 20 ⁇ l of the complement solution, and 10 ⁇ l of the diluent solution to give “antibody drug + complement addition” .
- Test sample 5 was prepared by diluting the ratatopherin hydrolysis mixture prepared in Production Example 1 with the dilution solution used in Test Example 1 to 1000 / g / ml.
- Lymphoma-derived cells Daudi obtained from ATCC CCL-213: American Type Culture Collection
- Raji obtained from American Type Culture Collection
- SKW6.4 ATCC TIB-215
- lymphoma-derived cells ARH-77 ATCC CRL-1621: obtained from the American Type Culture ⁇ collection
- the cell suspension was prepared by using the above-mentioned diluted solution as described above, and each cell solution was prepared, and each cell solution was added to a 24-well culture plate (manufactured by NUNC: catalog number 143982) at 100 / i 1 (2 ⁇ 10 5 cells). ) was added.
- the 24-well plate prepared as described above was cultured in an incubator (manufactured by Napco, catalog number 5300) under the conditions of 37 ° C and 5% carbon dioxide for 1 hour.
- the cells were collected, and the ratio of each dead cell was examined by the method using PI described above. Cytotoxic activity was calculated as 100% when all target cells were killed.
- ARH-77 a lymphoma-derived cell that is resistant to cytotoxic activity due to complement and antibodies (resistant to antibody drugs), has its resistance to cytotoxic activity by a ratatopherin hydrolysis mixture. It was confirmed that it had the effect of releasing. It is considered that the ratatoferrin hydrolysis mixture has the effect of increasing the sensitivity to cytotoxic activity against tumor cells resistant to the antibody drug and recovering the cytotoxic activity of complement and the antibody drug.
- the ratatophrine hydrolysis mixture produced in Production Example 1 was used as Sample A, and the ratatopherin hydrolyzed peptide (ratatoferin partial peptide) produced in Production Example 2 was used as Sample B.
- control samples commercially available Aspergillus extraferrin (manufactured by Morinaga Milk Co., Ltd.) was used as control A, and protamine sulfate (Protamine Sulfate) was used as control B.
- Raji cells in logarithmic growth phase were used as target cells.
- the Raji cells collected by centrifuging the cell suspension were suspended in a new culture solution (RPMI1640, 10% FCS), counted, and added to a 24-well plate at 1.0 ⁇ 10 5 / well.
- RPMI1640, 10% FCS a new culture solution
- PI Propidium iodide, lmg / ml
- sample B which is a component contained in sample A, also had an additive effect of enhancing the action of CDC (complement-dependent cytotoxicity).
- Control B which is a substance rich in basic amino acids and similar to sample B, was not confirmed to enhance the CDC reaction. It was also found that it did not affect the action to enhance From these results, it was found that the effect of enhancing the cytotoxic activity of the antibody drug and complement was a very specific effect on sample A (ratatopherin hydrolysis mixture) or sample B (ratatopherin partial peptide).
- Lactose (manufactured by Megre) 600 g, corn starch (manufactured by Nisshin Flour Milling Co., Ltd.) 400 g, crystal cell source (manufactured by Wako Pure Chemical Industries, Ltd.) 400 g and laura ferrin hydrolysis mixture 600 g produced in Production Example 1 were mixed with 50 g The sieve is sieved with a mesh sieve (manufactured by Yamato Scientific Co., Ltd.), placed in a 0.5 mm thick polyethylene bag, and mixed by inversion. A fully automatic capsule filling machine (manufactured by Cesere 'D2 Co., press type) is used.
- the above powder was filled in a capsule (made by Nippon Elancone Earth Co., Ltd., No. 1 gelatin capsule, Op. Yellow No. 6 Body, empty weight: 75 mg) with a content of 275 mg to enhance the cytotoxic activity of antibody drugs. 7000 capsules were obtained.
- the number of tablets was 10
- the tablet weight was 6.2 g
- the Monsanto hardness was 3.5-5.0 kg using an 8 mm diameter R punch.
- the tablet was tableted under the conditions set at a compression pressure to obtain 16 drugs having an effect of enhancing the cytotoxic activity of an antibody drug containing about 50% of the ratatofurin hydrolyzing peptide.
- the active ingredient of the drug for treating cancer in the present invention can be mass-produced because relatively inexpensive raw materials such as milk can be obtained.
- the agent of the present invention can efficiently kill target tumor cells by enhancing the cytotoxic activity of complement and antibody drugs. Furthermore, it has the effect of recovering the cytotoxic activity of complement and antibody drugs on tumor cells resistant to antibody drugs. That is, even if the malignant tumor resistant to the antibody drug recurs and the patient is judged to be difficult to treat with the antibody drug, the use of the agent of the present invention in combination with the antibody drug is continued. It responds to the desire to perform treatment at the hospital. This provides a novel guide to overcoming antibody drug resistance in cancer treatment.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05720394A EP1726310B1 (en) | 2004-03-19 | 2005-03-09 | Drug for cancer therapy |
ES05720394T ES2381189T3 (es) | 2004-03-19 | 2005-03-09 | Fármaco para terapia contra el cáncer |
AT05720394T ATE541581T1 (de) | 2004-03-19 | 2005-03-09 | Medikament für die krebstherapie |
AU2005224209A AU2005224209B2 (en) | 2004-03-19 | 2005-03-09 | Medicine for cancer therapy |
US10/564,302 US7419667B2 (en) | 2004-03-19 | 2005-03-09 | Drug for cancer therapy |
DK05720394.5T DK1726310T3 (da) | 2004-03-19 | 2005-03-09 | Lægemiddel til cancerterapi |
CN2005800007993A CN1838965B (zh) | 2004-03-19 | 2005-03-09 | 用于癌症治疗的药品 |
CA2533753A CA2533753C (en) | 2004-03-19 | 2005-03-09 | Drug for cancer therapy |
NZ544448A NZ544448A (en) | 2004-03-19 | 2005-03-09 | Medicine for cancer therapy containing a lactoferrin hydrolysate and antibody |
JP2006500608A JP3998702B2 (ja) | 2004-03-19 | 2005-03-09 | 癌治療のための薬剤 |
HK07100198.3A HK1093436A1 (en) | 2004-03-19 | 2007-01-05 | Medicine for cancer therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-080454 | 2004-03-19 | ||
JP2004080454 | 2004-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005089788A1 true WO2005089788A1 (ja) | 2005-09-29 |
Family
ID=34993444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004123 WO2005089788A1 (ja) | 2004-03-19 | 2005-03-09 | 癌治療のための薬剤 |
Country Status (14)
Country | Link |
---|---|
US (1) | US7419667B2 (ja) |
EP (1) | EP1726310B1 (ja) |
JP (1) | JP3998702B2 (ja) |
KR (1) | KR100773259B1 (ja) |
CN (2) | CN101444624B (ja) |
AT (1) | ATE541581T1 (ja) |
AU (1) | AU2005224209B2 (ja) |
CA (1) | CA2533753C (ja) |
DK (1) | DK1726310T3 (ja) |
ES (1) | ES2381189T3 (ja) |
HK (2) | HK1128113A1 (ja) |
NZ (1) | NZ544448A (ja) |
PT (1) | PT1726310E (ja) |
WO (1) | WO2005089788A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016056665A1 (ja) * | 2014-10-08 | 2016-04-14 | 学校法人慶應義塾 | 白血球の細胞外トラップ形成の阻害剤 |
JP2018531939A (ja) * | 2015-10-06 | 2018-11-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 治療用化合物及び方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005307199B2 (en) * | 2004-11-19 | 2011-04-28 | Fonterra Co-Operative Group Limited | Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
EP2104507A4 (en) * | 2006-12-21 | 2011-05-25 | Biokine Therapeutics Ltd | T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR CANCER THERAPY |
EP2197471A2 (en) * | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
CA2765345C (en) | 2009-06-14 | 2016-06-21 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
WO2013160895A1 (en) | 2012-04-24 | 2013-10-31 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
KR101455306B1 (ko) * | 2012-07-17 | 2014-10-27 | 엘에스엠 주식회사 | 세포 증식 촉진용 사람 락토페린의 펩신 가수분해물 및 이의 제조 방법 |
US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
CN109310733A (zh) | 2016-02-23 | 2019-02-05 | 百欧林纳克斯有限公司 | 治疗急性骨髓性白血病的方法 |
CN113354726B (zh) * | 2021-06-11 | 2022-12-27 | 南方科技大学 | 乳铁蛋白活性肽及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351337A (ja) | 1986-08-22 | 1988-03-04 | Snow Brand Milk Prod Co Ltd | 抗腫瘍剤 |
JPH05238948A (ja) | 1991-06-21 | 1993-09-17 | Morinaga Milk Ind Co Ltd | 高純度ラクトフェリシンの大量製造法 |
JPH07309771A (ja) | 1994-05-17 | 1995-11-28 | Morinaga Milk Ind Co Ltd | 非経口用抗腫瘍剤 |
JPH0873499A (ja) * | 1994-09-01 | 1996-03-19 | Snow Brand Milk Prod Co Ltd | 新規ペプチドおよび免疫賦活剤 |
US5656591A (en) | 1992-01-23 | 1997-08-12 | Morinaga Milk Industry Co., Ltd. | Antimicrobial agents and method for treating products therewith |
WO1998006424A1 (fr) | 1996-08-15 | 1998-02-19 | Morinaga Milk Industry Co., Ltd. | Inhibiteurs des metastases cancereuses administres par voie orale |
JP2818056B2 (ja) | 1990-09-07 | 1998-10-30 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
WO2000012542A2 (en) * | 1998-08-28 | 2000-03-09 | Alpharma As | Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties |
JP2002515893A (ja) * | 1997-02-03 | 2002-05-28 | ファーミング インテレクチュアル プロパティ ビーブイ | ヒトラクトフェリンおよびその改変体の有用な特性 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63186260A (ja) | 1987-01-28 | 1988-08-01 | Minolta Camera Co Ltd | 作像装置 |
JP3207647B2 (ja) | 1993-12-21 | 2001-09-10 | 森永乳業株式会社 | IgGおよびIgMクラスの抗体産生を促進する免疫賦活剤 |
JP3693377B2 (ja) | 1995-04-20 | 2005-09-07 | 森永乳業株式会社 | 生体内で感染防御作用を有するペプチド混合物と、このペプチド混合物を含有する組成物 |
JP2000229881A (ja) | 1999-02-10 | 2000-08-22 | Morinaga Milk Ind Co Ltd | 癌疾患の予後改善剤 |
-
2005
- 2005-03-09 AT AT05720394T patent/ATE541581T1/de active
- 2005-03-09 CN CN2008101795778A patent/CN101444624B/zh not_active Expired - Fee Related
- 2005-03-09 NZ NZ544448A patent/NZ544448A/en not_active IP Right Cessation
- 2005-03-09 KR KR1020067000743A patent/KR100773259B1/ko not_active IP Right Cessation
- 2005-03-09 DK DK05720394.5T patent/DK1726310T3/da active
- 2005-03-09 JP JP2006500608A patent/JP3998702B2/ja not_active Expired - Fee Related
- 2005-03-09 WO PCT/JP2005/004123 patent/WO2005089788A1/ja active IP Right Grant
- 2005-03-09 PT PT05720394T patent/PT1726310E/pt unknown
- 2005-03-09 AU AU2005224209A patent/AU2005224209B2/en not_active Ceased
- 2005-03-09 CN CN2005800007993A patent/CN1838965B/zh not_active Expired - Fee Related
- 2005-03-09 ES ES05720394T patent/ES2381189T3/es active Active
- 2005-03-09 CA CA2533753A patent/CA2533753C/en not_active Expired - Fee Related
- 2005-03-09 EP EP05720394A patent/EP1726310B1/en not_active Not-in-force
- 2005-03-09 US US10/564,302 patent/US7419667B2/en not_active Expired - Fee Related
-
2007
- 2007-01-05 HK HK09107583.9A patent/HK1128113A1/xx not_active IP Right Cessation
- 2007-01-05 HK HK07100198.3A patent/HK1093436A1/xx not_active IP Right Cessation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351337A (ja) | 1986-08-22 | 1988-03-04 | Snow Brand Milk Prod Co Ltd | 抗腫瘍剤 |
JP2818056B2 (ja) | 1990-09-07 | 1998-10-30 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
JPH05238948A (ja) | 1991-06-21 | 1993-09-17 | Morinaga Milk Ind Co Ltd | 高純度ラクトフェリシンの大量製造法 |
US5656591A (en) | 1992-01-23 | 1997-08-12 | Morinaga Milk Industry Co., Ltd. | Antimicrobial agents and method for treating products therewith |
JPH07309771A (ja) | 1994-05-17 | 1995-11-28 | Morinaga Milk Ind Co Ltd | 非経口用抗腫瘍剤 |
JPH0873499A (ja) * | 1994-09-01 | 1996-03-19 | Snow Brand Milk Prod Co Ltd | 新規ペプチドおよび免疫賦活剤 |
WO1998006424A1 (fr) | 1996-08-15 | 1998-02-19 | Morinaga Milk Industry Co., Ltd. | Inhibiteurs des metastases cancereuses administres par voie orale |
JPH1059864A (ja) | 1996-08-15 | 1998-03-03 | Morinaga Milk Ind Co Ltd | 経口がん転移抑制剤 |
JP2002515893A (ja) * | 1997-02-03 | 2002-05-28 | ファーミング インテレクチュアル プロパティ ビーブイ | ヒトラクトフェリンおよびその改変体の有用な特性 |
WO2000012542A2 (en) * | 1998-08-28 | 2000-03-09 | Alpharma As | Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties |
JP2002523517A (ja) * | 1998-08-28 | 2002-07-30 | アルファーマ エイ エス | 生物活性ペプチド |
Non-Patent Citations (13)
Title |
---|
APOPTOSIS, vol. 3, no. 3, 1998, pages 195 - 202 |
CYTOMETRY, vol. 8, no. 4, 1987, pages 421 - 426 |
ELIASSEN L.T. ET AL, ANTICANCER RES., vol. 22, no. 5, 2002, pages 2703 - 2710, XP002992894 * |
ELIASSEN L.T. ET AL, JOURNAL OF PEPTIDE SCIENCE., vol. 9, 2003, pages 510 - 517, XP002995890 * |
HATAKE K., BLOOD FRONTIER, vol. 12, no. 11, 2002, pages 65 - 71 |
IIGO M. ET AL, CLIN. EXP. METASTASIS., vol. 17, no. 1, 1999, pages 35 - 40, XP002992893 * |
OGURA M., SAISHIN IGAKU, vol. 58, no. 12, 2003, pages 102 - 121 |
ONCOGENE, vol. 22, 2003, pages 7359 - 7368 |
SAKURAI T. ET AL: "Lactoferrin Bunkaibutsu (LFH) no Rituximab ni yoru Hotai Izonsei no Saibu Shogai Sayo (CDC) ni Oyobosu Tenka Koka.", THE JAPANESE CANCER ASSOCIATION SOKAI KIJI., vol. 63RD, 25 August 2004 (2004-08-25), pages 308, XP002992891 * |
SAKURAI T. ET AL: "Rituximab ni yoru Hotai Izonsei no Saibo Shogai Sayo (CDC) ni Oyobosu Lactoferrin Bunkaibutsu (LFH) no Tenka Koka.", RINSHO KETSUEKI., vol. 45, no. 8, 30 August 2004 (2004-08-30), pages 915, XP002992892 * |
YOO Y.C. ET AL, ADV.EXP.MED.BIOL., vol. 443, 1998, pages 285 - 291, XP002995887 * |
YOO Y.C. ET AL, JPN.J.CANCER RES., vol. 88, no. 2, 1997, pages 184 - 190, XP002995889 * |
YOO Y.C. ET AL: "L", BIOCHEM.BIOPHYS.RES.COMMUN., vol. 237, no. 3, 1997, pages 624 - 628, XP002995888 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016056665A1 (ja) * | 2014-10-08 | 2016-04-14 | 学校法人慶應義塾 | 白血球の細胞外トラップ形成の阻害剤 |
JPWO2016056665A1 (ja) * | 2014-10-08 | 2017-08-10 | 学校法人慶應義塾 | 白血球の細胞外トラップ形成の阻害剤 |
JP2018531939A (ja) * | 2015-10-06 | 2018-11-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 治療用化合物及び方法 |
US11098100B2 (en) | 2015-10-06 | 2021-08-24 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
US11098101B2 (en) | 2015-10-06 | 2021-08-24 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
Also Published As
Publication number | Publication date |
---|---|
DK1726310T3 (da) | 2012-05-07 |
KR20060095899A (ko) | 2006-09-04 |
NZ544448A (en) | 2009-10-30 |
AU2005224209A1 (en) | 2005-09-29 |
EP1726310B1 (en) | 2012-01-18 |
AU2005224209B2 (en) | 2007-04-19 |
EP1726310A1 (en) | 2006-11-29 |
CN101444624A (zh) | 2009-06-03 |
CN101444624B (zh) | 2012-10-10 |
CN1838965B (zh) | 2011-07-06 |
US20060204501A1 (en) | 2006-09-14 |
EP1726310A4 (en) | 2009-06-24 |
ES2381189T3 (es) | 2012-05-23 |
HK1093436A1 (en) | 2007-03-02 |
ATE541581T1 (de) | 2012-02-15 |
CA2533753A1 (en) | 2005-09-29 |
KR100773259B1 (ko) | 2007-11-05 |
PT1726310E (pt) | 2012-04-27 |
JP3998702B2 (ja) | 2007-10-31 |
HK1128113A1 (en) | 2009-10-16 |
US7419667B2 (en) | 2008-09-02 |
CA2533753C (en) | 2012-10-16 |
CN1838965A (zh) | 2006-09-27 |
JPWO2005089788A1 (ja) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3998702B2 (ja) | 癌治療のための薬剤 | |
Kitts et al. | Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery | |
Nagpal et al. | Bioactive peptides derived from milk proteins and their health beneficial potentials: an update | |
JP2008509073A (ja) | カゼイン由来ペプチドおよびその治療的使用 | |
AU2014324901A1 (en) | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control | |
JP2003528827A (ja) | カゼイン由来ペプチドおよびその医療用途 | |
WO1997035875A1 (fr) | Peptide destine a inhiber l'elevation du taux de triglycerides dans le sang et agent d'inhibition contenant ce peptide en tant qu'ingredient actif | |
EP3590519A1 (en) | Glp-1 secretagogue and composition | |
AU2005302921B2 (en) | Protein hydrolysate with antidiabetic effect | |
US5543392A (en) | Digestive tract cell activating agent of EGF and lactoferrin | |
WO1998006424A1 (fr) | Inhibiteurs des metastases cancereuses administres par voie orale | |
JP3207647B2 (ja) | IgGおよびIgMクラスの抗体産生を促進する免疫賦活剤 | |
JP2022522725A (ja) | アルブミンと結合したSlit3タンパク質のLRRD2を含む骨関連疾患の予防または治療用組成物 | |
Jin Jr | Separation and purification of antidiabetic bioactive peptide from salmon and cod waste | |
JP6345630B2 (ja) | 新規ペプチド及びその用途 | |
Jauregi | Bioactive peptides from food proteins: new opportunities and challenges | |
JP2017048124A (ja) | アミノペプチダーゼa阻害剤 | |
WO1997000890A1 (en) | Peptide that inhibits blood triglyceride level rise and blood triglyceride level rise inhibitor containing said peptide as active ingredient | |
NZ576636A (en) | A method for screening for a substance having an action of proliferating natural killer cells | |
JP2001158748A (ja) | IgE産生抑制剤 | |
JP2000136148A (ja) | 細胞への付着阻害組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580000799.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006500608 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005224209 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 544448 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 84/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005720394 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10564302 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067000743 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2533753 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2005224209 Country of ref document: AU Date of ref document: 20050309 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005224209 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067000743 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10564302 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005720394 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2005224209 Country of ref document: AU |